VACCINEX, INC. Stockholders Equity

Quick Answer

VACCINEX, INC. reported Stockholders Equity of -$2.49 million for fiscal year 2024.

VACCINEX, INC. Stockholders Equity — Annual History

Fiscal Year Stockholders Equity YoY Change
2024 -$2.49M -7.7%
2023 -$2.31M -144.5%
2022 $5.19M -29.9%
2021 $7.41M +127.9%
2020 -$26.57M -1.3%
2019 -$26.24M -204.3%
2018 -$8.62M +93.1%
2017 -$125.45M -17.2%
2016 -$107.06M

Quarterly Stockholders Equity

Quarter Ending Stockholders Equity YoY QoQ
September 30, 2024 -$1.32M +65.9% +53.9%
June 30, 2024 -$2.86M -577.1% -207.9%
March 31, 2024 $2.65M +10.6% +214.9%
December 31, 2023 -$2.31M -144.5% +40.3%
September 30, 2023 -$3.87M -161.2% -814.7%
June 30, 2023 -$423.0K -103.9% -117.6%
March 31, 2023 $2.40M -85.2% -53.8%
December 31, 2022 $5.19M -29.9% -17.8%
  • VACCINEX, INC. showed a decrease of -7.7% in Stockholders Equity compared to the prior fiscal year.
  • Over the 2016–2024 period, VACCINEX, INC.’s stockholders equity has grown by 97.7% (from -$107.06 million to -$2.49 million).
  • The most recent figure is from VACCINEX, INC.’s fiscal year 2024 report (Form 10-K), filed with the SEC on April 15, 2025.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment